Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Brainstorm Cell Therapeutics Inc
Operating Expenses
Brainstorm Cell Therapeutics Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
|
Operating Expenses
-$12.3m
|
CAGR 3-Years
19%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-4%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$22.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$11.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$14.1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$5.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$8.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
Brainstorm Cell Therapeutics Inc
Glance View
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2003-05-28. The firm is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its phase III ALS and phase II PMS clinical trials. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd. holds the rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd., and two others.
See Also
What is Brainstorm Cell Therapeutics Inc's Operating Expenses?
Operating Expenses
-12.3m
USD
Based on the financial report for Mar 31, 2025, Brainstorm Cell Therapeutics Inc's Operating Expenses amounts to -12.3m USD.
What is Brainstorm Cell Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-4%
Over the last year, the Operating Expenses growth was 34%. The average annual Operating Expenses growth rates for Brainstorm Cell Therapeutics Inc have been 19% over the past three years , 14% over the past five years , and -4% over the past ten years .
